Nat. Biotechnol. 22, 145–147 (2004).
On p. 145, CTLA4-Ig is described as having achieved “outstanding phase 3 results.” In fact, the data were from a phase 2 trial.
Additional information
The online version of the original article can be found at 10.1038/nbt0204-145
Rights and permissions
About this article
Cite this article
Garber, K. Erratum: Make or break for costimulatory blockers. Nat Biotechnol 22, 341 (2004). https://doi.org/10.1038/nbt0304-341c
Issue Date:
DOI: https://doi.org/10.1038/nbt0304-341c
